Theravance-GSK's COPD drug wins support of FDA panel

04/18/2013 | Reuters · Bloomberg Businessweek

A panel of FDA advisers endorsed the approval of GlaxoSmithKline and Theravance's Breo Ellipta as a treatment for chronic obstructive pulmonary disease. The once-daily inhaled treatment, a combination of fluticasone furoate and vilanterol, would compete with GSK's Advair and AstraZeneca's Symbicort. The FDA could issue a decision by May 12.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR